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Abstract
Background: Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in Asia. Japanese
encephalitis (JE) caused by JEV is characterized by extensive inflammatory cytokine secretion, microglia activation,
blood-brain barrier (BBB) breakdown, and neuronal death, all of which contribute to the vicious cycle of
inflammatory damage. There are currently no effective treatments for JE. Mesenchymal stem cells (MSCs) have
been demonstrated to have a therapeutic effect on many central nervous system (CNS) diseases by regulating
inflammation and other mechanisms.
Methods: In vivo, 8- to 10-week-old mice were infected intraperitoneally with JEV and syngeneic bone marrow
MSCs were administered through the caudal vein at 1 and 3 days post-infection. The mortality, body weight, and
behavior were monitored daily. Brains from each group were harvested at the indicated times for hematoxylin
and eosin staining, immunohistochemical observation, flow cytometric analysis, TUNEL staining, Western blot,
quantitative real-time polymerase chain reaction, and BBB permeability assays. In vitro, co-culture and mixed culture
experiments of MSCs with either microglia or neurons were performed, and then the activation state of microglia
and survival rate of neurons were tested 48 h post-infection.
Results: MSC treatment reduced JEV-induced mortality and improved the recovery from JE in our mouse model.
The inflammatory response, microglia activation, neuronal damage, BBB destruction, and viral load (VL) were
significantly decreased in the MSC-treated group. In co-culture experiments, MSCs reprogrammed M1-to-M2
switching in microglia and improved neuron survival. Additionally, the VL was decreased in Neuro2a cells in the
presence of MSCs accompanied by increased expression of interferon-α/β.
Conclusion: MSC treatment alleviated JEV-induced inflammation and mortality in mice.
Keywords: Mesenchymal stem cells, Immunomodulation, Japanese encephalitis virus, Inflammation
Background
Viral encephalitis caused by multiple emerging and re-
emerging viruses is characterized by overwhelming
inflammation in the brain [1]. There are currently no
effective methods to eliminate the virus or to cure the
neuroinflammation, leading to thousands of people
succumbing to the devastating illness and the survivors
often suffering from permanent neurological deficits.
Japanese encephalitis (JE) caused by the JE virus (JEV)
is the most prevalent type of viral encephalitis [2].
JEV is a single-stranded, positive-sense RNA (~11 kb,
monopartite, linear) virus belonging to the genus Flavivi-
rus in the family Flaviviridae [3]. Globally, more than
67,900 cases of JEV infection are reported annually,
among which approximately 30% are fatal and 50% suffer
from permanent neuropsychiatric sequelae [4, 5]. Children
are more susceptible to JEV, but there is an increasing
occurrence in the middle-aged population [6]. Although
* Correspondence: yflei@fmmu.edu.cn; jiazsh@fmmu.edu.cn
†Equal contributors
2Department of Microbiology, School of Preclinical Medicine, the Fourth
Military Medical University, Xi’an 710032, China
1Department of Infectious Diseases, Tangdu Hospital, the Fourth Military
Medical University, Xi’an 710038, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bian et al. Stem Cell Research & Therapy  (2017) 8:38 
DOI 10.1186/s13287-017-0486-5
the development of a JE vaccine has markedly reduced the
incidence, its protection is not always effective [7]. JE is
characterized by extensive neuroinflammation in the cen-
tral nervous system (CNS) with robust and uncontrolled
production of pro-inflammatory cytokines (e.g., tumor
necrosis factor (TNF)-α and interferon (IFN)-γ) and che-
mokines (e.g., MCP-1/CCL2) [8–11]. Increased activation
of microglia following JEV infection also contributes to
the inflammatory response. During JE, neurons can be
damaged by JEV directly or indirectly by the cytokine
storm through the bystander effect [12]. Meanwhile,
breakdown of the blood-brain barrier (BBB) integrity also
accelerates the progression of JE [13]. There are currently
no effective anti-JEV or other satisfactory therapeutic
methods but life-sustaining treatment [14].
Mesenchymal stem cells (MSCs) have been demon-
strated to contribute to tissue regeneration and modu-
late inflammation since they were first discovered by
Friedenstein in 1974 [15, 16]. MSCs have the capacity
for immunoregulation, the potential to migrate to the in-
jury site, and the ability to differentiate into multiple cell
types such as adipocytes, osteocytes, chondrocytes, and
neuron-like cells. All of these properties have been bene-
ficial in treating a wide spectrum of diseases in clinical
and basic studies [17–19]. It has been reported that
transplantation of MSCs can upregulate the expression
of brain-derived neurotrophic factor (BDNF) and nerve
growth factor (NGF), and can improve neurological re-
covery in many CNS diseases [20–23]. MSCs also con-
trol local inflammation and maintain tissue homeostasis
by enhancing the innate and adaptive immune responses
as well as regulating the activation and function of
microglia [24, 25]. In addition, MSCs regulate BBB in-
tegrity by promoting the expression of vascular endothe-
lial growth factor and angiogenesis [26–28]. Thus, the
functional features of MSCs indicate their great potential
in JE treatment. However, it is unknown whether MSCs
can attenuate the encephalitis caused by JEV.
This study is the first to show that MSC treatment
reduced the mortality and neurological pathology in the
mouse model of JE. We also demonstrated that the
beneficial effect of MSCs was mediated by suppressing
the overactivation of microglia, reducing neuronal death,
and improving the integrity of the BBB. Furthermore, we
found that MSCs decreased JEV replication through the
expression of IFN-β and IFN-α.
Methods
Ethics statement
All the mice used in this experiment were purchased from
the Laboratory Animal Center of the Fourth Military
Medical University (FMMU). All animal experiments were
approved by the Animal Care and Use Committee of the
FMMU.
Isolation and culturing of mouse bone marrow MSCs
The mouse bone marrow-derived MSCs were isolated
by the adhesive screening method [29]. Female BALB/c
mice (aged 4 to 6 weeks) were euthanized by cervical
dislocation and sterilized with 75% alcohol for 3 to
5 min. The femurs were removed, and both ends of
each femur were cut off. The marrow cavities were then
flushed with low-glucose Dulbecco’s modified Eagle’s
medium (L-DMEM; Gibco, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS; Gibco, Grand
Island, NY, USA) and 1% penicillin-streptomycin
(Gibco, Grand Island, NY, USA) repeatedly until the
femurs turned white. The cell suspension was gently
pipetted to separate the cells, transferred to a 15-ml
centrifuge tube, and centrifuged at 1000 rpm for 5 min.
The cell pellets were then resuspended in 5 ml L-
DMEM, plated in 25-cm2 flasks, and cultured at 37 °C
in an atmosphere with 5% CO2 and saturated humidity.
After 24 h, the medium was first changed, with subse-
quent changes occurring every 3 days to remove the
nonadherent cells. Plastic-adherent cells were cultured
to 95% confluency and passaged with trypsinization.
MSCs used in this study were from passages 5-8th and
analyzed by flow cytometry (defining criteria: >95% posi-
tive for the stem cell surface antigens CD44 and Sca-1,
and <5% negative for CD45, CD34, and I-A/I-E) and
multi-differentiation evaluation (adipocytes, osteocytes,
and chondrocytes, using the Mouse Mesenchymal Stem
Cell Functional Identification Kit (Cyagen, China)) before
the experiments (see Additional file 1: Figure S1).
Cells and virus
The JEV SA-14 strain was propagated in the mosquito
cell line C6/36. The supernatant containing JEV was
concentrated at 100:1 and stored in aliquots at –80 °C
until further use. The virus stocks were titrated by a
conventional plaque assay [30].
The microglia cell line N9 and the neuroblast cell line
Neuro2a were purchased from ATCC and maintained in
5% FBS DMEM and 10% FBS DMEM, respectively.
MSC transplantation into JEV-infected mice
Weight-matched adult female BALB/c mice (8–10 weeks
old) were randomly divided into three groups: control
group (phosphate-buffered saline (PBS)); JEV-infected
group (JEV); and JEV-infected and MSC-treated group
(JEV +MSC). The JEV and JEV +MSC mice were intra-
peritoneally injected with 5 × 107 PFU of JEV in 200 μl
PBS. For the cellular injections, 200 μl of either PBS alone
or MSCs (5 × 105 cells per mouse) were intravenously ad-
ministered to mice belonging to the JEV and JEV +MSC
groups, respectively, at 1 and 3 days post-infection (dpi).
The mice in each group were monitored daily to assess
behavior, weight, and mortality. Behavioral scoring was
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performed according to the criteria previously described
with minor modifications [31], and the mean scores of all
mice in each group were calculated. After the comparative
observations were repeated three times, we found an
obvious difference in the manifestation of the clinical
syndrome between the JEV and JEV +MSC groups from 6
dpi. Subsequently, new models and treatments were
conducted and brains were collected at 6 dpi for further
experiments.
Quantitative real-time polymerase chain reaction (qRT-PCR)
At 6 dpi, mice were anesthetized with 2% pentobarbital
sodium (0.1 ml/10 g body weight) and perfused with 1×
PBS, and then the whole brain of each mouse from all
the groups was harvested and stored at –80 °C. Viral
burden and the expression of cytokines and chemokines
were determined by relative qRT-PCR (see Additional
file 2: Table S1 for the primer sequences). Total RNA
from each whole brain and the in vitro cultured cells
was extracted with RNAfast1000 (PIONEER, China).
The first-strand cDNA was prepared by reverse tran-
scription with total RNA as the template using a Prime-
Script RT reagent Kit (TaKaRa, Japan). All qRT-PCR
experiments were performed using SYBR Green Real-
Time PCR Master Mix (TaKaRa, Japan) according to the
manufacturer’s instructions.
Hematoxylin and eosin (H&E) and immunohistochemical
(IHC) staining
At 6, 10, and 22 dpi, mice were anesthetized with 2%
pentobarbital sodium (0.1 ml/10 g body weight) and per-
fused with 1× PBS followed by 4% paraformaldehyde
(PFA) for 30 min. The brain was removed, fixed in 4%
PFA for 12 h, and then cryoprotected in 30% sucrose.
Tissue sections of 10 μm thickness were prepared with a
vibratome. The standard H&E staining protocol was
followed for tissue staining. For IHC staining, primary
antibodies were incubated at room temperature for 16 h.
Corresponding secondary antibodies were then incu-
bated for 4 h at room temperature protected from light
(see Additional file 3: Table S2 for the antibodies). The
nuclei were counterstained with DAPI (100 ng/ml;
Sigma, St. Louis, MO, USA), and coverslips were placed
on the samples with 50% glycerol in PBS.
TUNEL staining
TUNEL staining of the sections was performed using an
In Situ Cell Death Detection Kit (Roche, Germany)
according to the manufacturer’s instructions. The nuclei
were counterstained with DAPI.
Western blotting
Total protein from the brain of each mouse was
extracted with RIPA buffer and quantified using a
Protein Reagent Assay BCA Kit (Thermo, Waltham,
MA, USA). Thirty micrograms of protein from each
sample was loaded and electrophoresed using 15% SDS-
PAGE gels and then transferred onto a polyvinylidene
difluoride (PVDF) membrane (Millipore, Billerica, MA,
USA). After the membranes were blocked with 3%
bovine serum albumin (BSA) at room temperature for
60 min, they were incubated with primary antibodies
overnight at 4 °C. Then, the blots were incubated
with secondary antibody for 2 h at room temperature
(see Additional file 3: Table S2 for the antibodies
used). The blots were visualized using an Infrared Im-
aging System (Odyssey, LI-COR, NE Lincoln, USA).
BBB permeability assay
BBB permeability was determined by visualizing and
quantifying the levels of extravasated Evans blue dye
(EB) in the brain. Mice were injected intraperitoneally
with 0.4 ml 2% (w/v) EB (Sigma, St. Louis, MO, USA)
followed by euthanization and intracardiac perfusion
with PBS 1 h later. The brains were subsequently
removed and photographed. For quantification, brain
tissues were weighed and homogenized in 1 ml PBS, and
then 1 ml 100% trichloroacetic acid (Sangon, China) was
added. The mixture was vigorously shaken for 2 min to
precipitate the proteins and cooled for 30 min at 4 °C.
After the mixture was centrifuged (30 min at 6000 g),
the absorbance of the supernatant was measured at
620 nm using a spectrophotometer. The content of EB
was quantified as nanograms of dye per gram of brain
tissue using a standard curve.
Neuro2a cells and MSC co-culture experiment
Neuro2a cells were plated in the basolateral chamber of
a six-well transwell (3.0 μm, polycarbonate membrane
tissue culture-treated polystyrene; Costar, Corning, NY,
USA) at a density of 2 × 105/well, and 1 × 105 MSCs were
added to the inserts and separately incubated overnight.
The Neuro2a cells were then infected with JEV (multi-
plicity of infection (MOI) = 1). After adsorption for 1 h,
the old virus suspension was removed, and fresh DMEM
was added to the Neuro2a cells; subsequently, the trans-
well inserts containing either MSCs or DMEM alone were
placed into their corresponding wells. The cells were
harvested for qRT-PCR and flow cytometry after 48 h.
For mixed cultures of Neuro2a cells and MSCs, the
Neuro2a cells were plated in six-well plates at a density
of 2 × 105/well with ten-fold diluted numbers of MSCs
(ranging from 200 to 2 × 105). After the cells were incu-
bated in DMEM overnight, they were infected with JEV
at an MOI = 1; 48 h later, the cells were harvested for
detection of the viral load. Additionally, Neuro2a cells
were plated in six-well plates at a density of 2 × 105/well
with MSCs (2 × 104). After the cells were incubated in
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DMEM overnight, they were infected with JEV at a
MOI = 0.1 and then harvested at 24, 48, 72, and 96 h
post-infection for detection of the viral load.
N9 cell and MSC mixed culture experiment
N9 cells were plated in six-well plates at a density of
2 × 105 with or without MSCs (2 × 104) and incubated
overnight, after which JEV (MOI = 5) was inoculated
as described above, and the cells were harvested after
48 h for flow cytometry and qRT-PCR analysis.
Flow cytometric analysis
For annexin V/PI staining, an Annexin V-FITC Apop-
tosis Kit (BD Biosciences, Franklin lakes, NJ, USA) was
used. The cells were washed and incubated for 15 min at
room temperature with annexin V labeled with FITC
and propidium iodide (PI).
Both primary cells from mouse brains and N9 cells
were stained with FITC anti-mouse F4/80 and PE
anti-mouse MR (CD206) for 50 min at 4 °C. After
the cells were washed, they were permeabilized and
stained with APC-anti-mouse iNOS for 50 min. Ana-
lysis was conducted using a BD FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA).
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 6.01 software (La Jolla, CA, USA). Data
represent the mean ± standard error of the mean (SEM).
Significant differences between the experimental groups
were determined using Student’s t test. P values < 0.05
were considered significant.
Results
MSC treatment protects mice from JEV infection-induced
lethality
It has been shown that MSCs can relieve inflammation-
induced tissue damage during the infection of viruses
and bacteria through immunomodulation [32–34]. To
assess the effect on the progression of JE, MSCs were
transplanted at 1 and 3 dpi. In general, JEV-infected
mice without MSC treatment showed clinical signs of
encephalitis starting with piloerection and physical limi-
tation followed by paresis and rigidity, and eventually
progressing to severe neurological signs such as paraly-
sis, seizure, and even death. In contrast, the MSC treat-
ment group had a more rapid recovery in terms of
weight and behavior than the JEV group (Fig. 1a and b).
The survival rate was significantly improved in the MSC
treatment group (77.78% survival) compared with the
JEV group (36.84% survival) (Fig. 1c). These data
suggested that MSC treatment alleviated the suffering
and improved the prognosis in JEV-infected mice.
Fig. 1 MSC treatment protects mice from JEV infection-induced
lethality. Mice were given phosphate-buffered saline (PBS) (n = 7) or
Japanese encephalitis virus (JEV) (n = 36) by intraperitoneal injection.
Then, the mice were intravenously injected with either PBS or
mesenchymal stem cells (MSCs) at 1 and 3 dpi via the tail vein. a
The weight of the mice in each group was recorded between 16:30
and 17:00 daily for 22 days until all the groups were completely
stable (PBS = 7, JEV = 18, JEV + MSC = 18). b The behavior scores
were monitored and recorded twice a day according to the scoring
criteria; the data are presented as the mean ± 95% confidence
interval (0 = no piloerection, no restriction of movement, no body
stiffening, no hind limb paralysis; 1 = piloerection, no restriction of
movement, no body stiffening, no hind limb paralysis; 2 = piloerection,
restriction of movement, no body stiffening, no hind limb paralysis;
3 = piloerection, restriction of movement, body stiffening, no hind
limb paralysis; 4 = piloerection, restriction of movement, body
stiffening, hind limb paralysis; 5 = piloerection, restriction of movement,
body stiffening, hind limb paralysis, occasional tremor or death. The
dead mice were scored as 5 and removed from the cohort). c The
death and survival of the mice were recorded every day and then
analyzed and presented as Kaplan–Meier survival curves
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Fig. 2 MSC transplantation attenuates the JEV-induced inflammatory response in mouse brains. Mice in each group were euthanized at 6 dpi, and the
histopathological alterations and inflammatory cytokines in the brain were investigated via H&E staining and qRT-PCR, respectively. a Severe meningitis in
Japanese encephalitis virus (JEV)-infected mice as indicated by arrows; this disease state was significantly alleviated in the mesenchymal stem cell (MSC)
treatment group. b Perivascular cuffing with increased inflammatory cell infiltration was more evident in JEV-infected mice compared with the MSC
treatment group. c Phagocytosis of neurons by inflammatory cells was apparent in JEV-infected mice (phosphate-buffered saline (PBS) n= 3, JEV n= 6,
JEV +MSC n= 6). d Total RNA from each brain was extracted, and the inflammatory cytokine levels were tested by qRT-PCR. There was decreased
expression of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and chemokine (C-C motif) ligand 2 (CCL-2) in the brains
from the MSC treatment group compared to JEV-infected mice (PBS n= 2, JEV n= 5, JEV +MSC n= 5). e When co-cultured with JEV-infected Neuro2a
cells via transwells, the expression of TSG-6 and transforming growth factor-β (TGF-β) in MSCs was increased, which might contribute to the alleviated
inflammation. The data represent the mean ± SEM for three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. 1 MSCs, 2 MSCs co-cultured
with JEV-infected Neuro2a cells
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MSC transplantation attenuates the inflammatory
response in JEV-infected mouse brains
Neuroinflammation is a key element in the progression
of JE. To observe changes in the inflammatory response
between the JEV group and MSC treatment group, the
histopathology and cytokine levels were detected. Histo-
logical alterations in the brain revealed severe meningitis
in JEV-infected mice at 6 dpi, which was significantly
alleviated in the MSC treatment group (Fig. 2a). There
was more remarkable inflammatory cell infiltration in
the cortexes of the JEV-infected group than in those of
the MSC treatment group. Meanwhile, the level of peri-
vascular cuffing showed a marked decrease in the MSC-
treated group (Fig. 2b). There were many sieged and
swallowed nerve cells in JEV-infected mice, which were
rare in the MSC treatment group (Fig. 2c). The allevi-
ated neuroinflammation in the JEV +MSC group was
also observed at 10 dpi, while there was no significant
difference between the JEV and JEV +MSC groups
regarding meningitis and perivascular cuffing since the
neuroinflammation has been resolved in survivors at 22
dpi (see Additional file 4: Figure S2). The levels of the
main inflammatory cytokines and chemokines in the
JEV +MSC group were generally reduced compared to
the JEV group (Fig. 2d). In vitro, there was increased
expression of the cytokines transforming growth factor
(TGF)-β and TSG-6 in MSCs co-cultured with JEV-
infected Neuro2a cells, which might play an important
role in the anti-inflammatory effects (Fig. 2e). Thus
MSC transplantation significantly suppressed inflammatory
lesions during JE.
MSC transplantation inhibits the activation of microglia
and regulates M1-to-M2-like phenotypic switching
Activated microglia play a central role in the pathogen-
esis of JE. To evaluate the effect of MSCs on microglia,
ionized calcium binding adaptor molecule-1 (IBA-1), the
marker of microglia activation, was stained in brain
sections. Plentiful activated microglia were observed
in the JEV-infected group while they were reduced in
the MSC-treated group (Fig. 3a). Meanwhile, the num-
ber of inflammatory macrophages (as indicated by F4/
80+iNOS+ cells) in the brain was also decreased after
MSC transplantation (Fig. 3b).
It has been reported previously that different stimula-
tion could polarize the microglia into the M1 phenotype
(pro-inflammation) marked by iNOS and CD86 or the
M2 phenotype (anti-inflammation) marked by Arg1 and
CD206. To verify the effect of MSCs on the activation of
microglia, mixed culturing of MSCs and the microglia
cell line N9 was performed in vitro. The expression of
iNOS and CD86 in N9 cells was induced by JEV infec-
tion, while it was decreased in the presence of MSCs. In
contrast, the expression of arginase-1 (Arg1) and CD206
(which contribute to the phagocytosis of pathogens and
presentation of antigen) was upregulated in N9 cells
when co-cultured with MSCs (Fig. 3c and d). Thus,
MSC transplantation inhibited JEV-induced overactiva-
tion of microglia as well as regulated the M1-to-M2-like
phenotypic switching.
MSCs reduce neuronal death in vivo and in vitro
Massive neuronal death leads to progression and deteri-
oration of JE. To explore whether MSCs could improve
the neuronal viability, neuron-specific nuclear protein
(NeuN; a marker of neurons)-positive cells were counted
in brain sections from the different groups. There were
more surviving neurons in the MSC-treated mice
(Fig. 4a). According to the TUNEL assay (Fig. 4b) and
Western blot (Fig. 4c), MSC treatment effectively de-
creased neuronal apoptosis. There was a decreased level
of active caspase-3 subunit P17 and increased expression
of B-cell lymphoma-2 protein (BCL2; an anti-apoptotic
protein) in MSC-treated mouse brains compared with
the JEV group. In vitro, the direct role of MSCs on neu-
rons was evaluated through transwell co-culture. More
Neuro2a cells survived when co-cultured with MSCs
than did solo cultures (Fig. 4d). These data indicated
that MSC treatment reduced neuronal loss.
MSC transplantation alleviates virus-induced BBB destruction
and improves the expression of ZO-1 in the mouse brain
It has been established that MSCs could regulate epithe-
lial cells and stabilize the integrity of the BBB in many
CNS diseases through a paracrine effect [32]. To
determine the effect of MSC treatment on BBB integrity
during JEV infection, an EB assay was performed. In
general, there was no significant difference in the ap-
pearance of color between control and JEV +MSC
groups. However, the brains from JEV-infected mice
were slightly tinged blue (Fig. 5a). Based on the amount
of EB retained in the brains, mice in the JEV +MSC
group showed reduced permeability of the BBB com-
pared with the JEV-infected group (Fig. 5b). Further-
more, there was higher expression of zonula occludens-1
(ZO-1) in the JEV +MSC group than the JEV-infected
group (Fig. 5c and d). Therefore, MSC treatment could
improve the expression of ZO-1 and reduce the JEV-
induced breakdown of the BBB.
MSCs prevent JEV propagation via interferon expression
Although MSCs inhibited the neuroinflammation in-
duced by JEV infection, it was unknown whether the
alleviated inflammation led to uncontrolled amplification
of the virus. Thus, we tested the titer of JEV in the
brains at 6 dpi from each group by immunofluorescence
(Fig. 6a) and qRT-PCR (Fig. 6b). The viral load was
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Fig. 3 (See legend on next page.)
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generally decreased in the JEV +MSC group compared
with the JEV group.
To verify the role of MSCs on JEV proliferation, a
series of mixed cultures of Neuro2a cells and MSCs were
conducted. The viral load was decreased as the number
of co-cultured MSCs increased (Fig. 6c, left). Meanwhile,
there was significantly lower viral copy and slower pro-
liferation in Neuro2a cells when co-cultured with MSCs
compared with the control group (Fig. 6c, right). Be-
sides, through transwell co-culture system, the viral copy
number in the Neuro2a cells was reduced accompanied
with increased expression of IFN-β and IFN-α in MSCs
(Fig. 6d). Therefore, these data indicated that MSCs
could inhibit the propagation of JEV in Neuro2a cells.
Discussion
Recently, there have been an increasing number of studies
on the therapeutic effect of MSCs on CNS diseases and
virus infection. It was reported that MSCs promoted neuro-
logical recovery via regulating neuroinflammation and se-
creting neurotrophic factors. In addition, exogenous MSC
transplantation has been demonstrated to reduce influenza
virus-induced acute lung injury [32, 34]. In our study, we
found that MSC transplantation improved the survival rate
and alleviated neurological symptoms in a JEV-infected
mouse model. These findings are the first evidence that
MSCs could serve as a potential adjunctive therapy for JE.
There are many ways to construct a JEV infection
mouse model, such as intracerebral injection, intraven-
ous injection, and intraperitoneal injection. Based on
feasibility and noninvasion, we adopted intraperitoneal
injection for our study. In this study, mice older (8–10
weeks of age) than those previously reported in a JE
mouse model (4–6 weeks of age) were used, and the
dose of inoculated JEV was slightly higher than the me-
dian lethal dose (LD50). In our preliminary experiments,
there was no obvious difference in the neurological
symptoms and histopathology between the younger and
older mouse model. JEV-infected mice generally began
to exhibit typical symptoms at 3 dpi. There was an
increased risk of pulmonary embolism when the number
of intravenously transplanted cells was more than 5 × 105,
and thus two intravenous injections of 5 × 105 cells/mouse
were conducted at 1 and 3 dpi. In this study, we focused
on the effect of MSCs on the acute neuroinflammation;
thus, brains from each group were collected at 6 dpi.
The overproduction of inflammatory cytokines is the
main cause of neuropathology during JE. Thus, inhibit-
ing the inflammation during the progression of JE has
been shown to reduce neuronal death and promote
neurogenesis [35]. An appropriate immune and inflam-
matory response during the early phase of infection is
critical for clearance of the virus and regeneration of the
nervous system [36]. However, the overproduction of
IFN-γ and TNF-α accelerated the neuroinflammation,
and neutralization of these inflammatory cytokines could
reduce the neuronal damage during JEV infection [37, 38].
Thus, it is important to achieve a balance between
immune and inflammatory responses for the treatment of
JE. MSCs are characterized by immunoregulation and
have shown great potential in the treatment of immune
deficiencies and infectious diseases [25, 39]. In this experi-
ment, MSC-treated mice showed decreased level of IFN-γ
and TNF-α at 6 dpi. Although the effect of these
decreased cytokines in the course of JE is uncertain, it was
well demonstrated that the neuroinflammation was allevi-
ated in the MSC-treated mice according to tissue patho-
logical changes. The dynamic regulation of MSCs during
JE, which might be involved in the increased immune
defenses to speed up the clearance of virus in the early
stage of infection, is worth further exploration.
Previous studies have shown that breakdown of the
BBB can exacerbate the progression of JE [13]. It has
been demonstrated that MSCs can improve the barrier
function of epithelial cells through the production of the
growth factors Ang1 and KGF, as well as regulating the
integrity of the BBB through the expression of TIMP3
(tissue inhibitor of matrix metalloproteinase-3) [32]. Our
results indicated that the BBB permeability was amelio-
rated in MSC transplanted mice compared to the PBS-
treated group. One possible explanation is that MSCs
could inhibit the excessive production of inflammation
cytokines and the overactivation of glia, both of which can
lead to the degradation of ZO-1 [13] and the subsequent
destruction of the BBB. However, the direct effect of MSCs
on the BBB during JEV infection is still being explored.
(See figure on previous page.)
Fig. 3 MSC transplantation inhibits the activation of microglia and regulates the M1-to-M2-like phenotypic switching. a The activation of microglia
was detected by anti-IBA-1 antibody with the boxed areas showing a higher magnification (left), and the intensity of IBA+ cells of each group was
analyzed with ImageJ (right) (PBS n= 3, JEV n= 6, JEV +MSCs n= 6; three sections per animal, five fields per section). b Total brain tissue was harvested,
and the percentage of F4/80+ iNOS+ cells (left), which represents the M1 polarized macrophages in the brain, was calculated; the mean of the percentage
(right) of M1 macrophages from each group was summarized (PBS n= 2, JEV n= 3, JEV +MSC n= 3). c In vitro cultures of the microglia line N9 with or without
MSCs (10:1, respectively) were infected with JEV (MOI = 5, 48 h), and the expression levels of the M1 marker iNOS and the M2 marker MR (CD206) were
analyzed by Flow Jo. d The expression levels of Arg1 and CD206 (markers for M2) as well as iNOS and CD86 (markers for M1) in N9 and N9-MSC cultures
either with or without JEV infected with JEV (MOI = 5, 48 h) was detected by qRT-PCR. The data represent the mean ± SEM for three independent
experiments. *P< 0.05, **P < 0.01, ****P < 0.0001. Arg1 arginase-1, IBA-1 ionized calcium binding adaptor molecule-1, iNOS inducible nitric oxide synthase,
JEV Japanese encephalitis virus, MSC mesenchymal stem cell, PBS phosphate-buffered saline
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It is well known that activation of microglia can trigger
a secondary pathway of damage and influence the
outcome of JEV progression [11, 40]. Our data indi-
cated that MSCs could inhibit the activation of
microglia. Meanwhile, when co-cultured with MSCs,
JEV-challenged N9 microglia cells showed increased
expression of Arg1 and CD206, the markers of the
M2 phenotype. These data are consistent with a pre-
vious study that MSCs reprogrammed microglia into
a M2-like phenotype to inhibit the overproduction of
inflammatory mediators and promote the regeneration
of tissue [41].
Fig. 4 MSCs reduce neuronal death in vivo and in vitro. Mice undergoing different treatments were euthanized at 6 dpi. a The survival rate of neurons
was detected with anti-NeuN antibody staining. b The TUNEL assay was performed to detect neuronal apoptosis, and the sections from each group were
analyzed with ImageJ. The positively stained cells were counted (PBS n= 3, JEV n = 6, JEV +MSC n= 6; three sections per mouse, five fields per section).
c The total protein of whole brain tissue was extracted, and the expression levels of the active caspase-3 subunit P17 (caspase-3 p17) and BCL2 in the
brains of each group were detected by Western blot (PBS n= 1, JEV n= 2, JEV +MSC n= 2). d Neuro2a cells were cultured via transwells either with or
without MSCs and were infected with JEV at MOI = 1. After 48 h, annexin V/PI staining was performed, and the mean of the survival rate was
summarized from three independent experiments. **P < 0.01, ***P < 0.001, ****P< 0.0001. BCL2 B-cell lymphoma-2 protein, JEV Japanese encephalitis virus,
MSC mesenchymal stem cell, NeuN neuron-specific nuclear protein, PBS phosphate-buffered saline, PI propidium iodide
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After JEV infection either in vivo or in vitro, there is a
significant production of TNF-α. It has been demon-
strated that MSCs can secrete TSG-6 (TNF-α stimulated
gene/protein 6) upon the induction of TNF-α to modu-
late inflammatory responses, inhibit the destruction of
the BBB, and ameliorate tissue injury [42, 43]. In vitro,
we found that upon co-culturing with JEV-infected Neu-
ro2a cells, MSCs showed increased expression of TSG-6
and TGF-β, and the Neuro2a cells exhibited decreased in-
flammatory cytokine expression and increased survival.
The role and mechanism of TSG-6 from MSCs in the alle-
viation of neuroinflammation during JE are still in research.
In addition to the regulation of inflammation, the
immune defense function of MSCs has also been dem-
onstrated in many bacteria- and virus-induced injuries
[32, 33, 44]. To our knowledge, there are few reports
about the antiviral role of MSCs. Interestingly, we found
statistically decreased viral load in MSC-treated mice. In
addition, the JEV titer in Neuro2a cells was decreased
when co-cultured with MSCs. One reason for this
phenomenon is that the immunomodulation of MSCs
can improve the innate and adaptive immune responses
and contribute to the elimination of virus. Moreover, in
this study, MSCs co-cultured with JEV-infected Neuro2a
cells showed significantly increased expression of IFN-β
and IFN-α compared with control cells. It is well known
that type I interferons play a key role in the defense
against JEV [45]. Furthermore, a series of changes in
genes related to antiviral activity in MSCs were detected
after either JEV stimulation or co-culturing with JEV-
infected Neuro2a cells through gene expression profiling
in our study (data unpublished). It has been reported that
MSCs can exert antibacterial effects by secretion of beta-
defensin-2 via Toll-like receptor 4 (TLR4) [33]. Whether
MSCs have a direct antiviral effect and the exact mechan-
ism is currently being explored.
Recently, engineered MSCs have also been developed to
exert more effective antiviral activities. As previously
reported, MSCs with a transgene encoding humanized
Venezuelan equine encephalitis virus (VEEV) neutralizing
antibody (anti-VEEV) had a more efficacious protective
effect in nude mice infected with VEEV [46]. However, the
protection of sham MSCs transplanted via intramuscular
injection was poor in the VEEV infection model [46]. In
Fig. 5 MSC transplantation alleviates virus-induced disintegration of the BBB and improves the expression of ZO-1 in the mouse brain. Mice from each
group were euthanized to detect the integrity of the BBB at 6 dpi. a BBB permeability was evaluated by the uptake of Evans blue dye assay (EB), and the
brains were removed and photographed. These pictures show extravasated EB staining of the whole brain at 6 dpi. b The absorbance of EB in the brain
was measured at 620 nm using a spectrophotometer and recorded as nanograms of dye per gram of brain tissue (PBS n= 2, JEV n= 3, JEV +MSC n= 3).
c The expression of the tight junction protein zonula occludens-1 (ZO-1) in the brain sections was assessed by immunofluorescence. d The fluorescence
intensity of ZO-1 staining was analyzed using ImageJ and showed that MSC treatment increased the level of ZO-1 compared with the JEV-infected group
(PBS n= 3, JEV n= 6, JEV + MSC n= 6; three sections per mouse, five fields per section). **P < 0.01, ***P < 0.001. JEV Japanese encephalitis virus,
MSC mesenchymal stem cell, PBS phosphate-buffered saline
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Fig. 6 MSCs prevent JEV propagation via interferon expression. a The viral load of JEV in the brain was assessed by detecting E protein through
immunofluorescence, and the fluorescence intensity was analyzed using ImageJ (PBS n= 3, JEV n= 6, JEV +MSC n= 6; three sections per mouse, five
fields per section). The staining showed that MSC treatment decreased the viral load in mice brains at 6 dpi. b Total RNA of the whole brain from each
mouse was extracted, and the viral load of JEV was assessed by qRT-PCR (PBS n= 2, JEV n= 5, JEV +MSC n= 5) at 6 dpi. c For the in vitro experiments,
Neuro2a cells were co-cultured with different numbers of MSCs and infected with JEV at multiplicity of infection (MOI) = 1, and the viral titer was
detected 48 h later by qRT-PCR (left panel). Neuro2a cells and MSCs were co-cultured at a ratio of 1:1, and JEV was added at MOI = 0.1. The cells were
then harvested at 24, 48, 72, and 96 h after infection, and the viral titer was determined by qRT-PCR (right panel). d Neuro2a cells were co-cultured with
MSCs in a noncontact transwell system at a ratio of 10:1, and Neuro2a cells were infected with JEV at MOI = 1. The Neuro2a cells and MSCs were
harvested 48 h later, and the viral copy number in Neuro2a cells and the expression of interferon (IFN)-β and IFN-α in MSCs was detected by qRT-PCR.
The data represent the mean ± SEM for three independent experiments. *P < 0.05, **P < 0.01. 1 MSCs, 2 MSCs co-cultured with JEV-infected Neuro2a
cells, JEV Japanese encephalitis virus, MSC mesenchymal stem cell, PBS phosphate-buffered saline
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our study, we found that MSC transplantation via intra-
venous injection increased the survival and reduced the
weight loss of JEV-infected mice. This divergence be-
tween the VEEV and JEV results might due to the
different pathogenic mechanisms, mouse models used,
and transplantation means applied.
In this study, we focused on the effects of MSCs on
the morbidity and acute neuroinflammation during JEV
infection and harvested mouse brains at 6 dpi. Whether
MSC transplantation improves neurological function
and prognosis during the late stage of encephalitis is also
being explored by our group.
Conclusion
Taken together, this study demonstrated that MSCs
exerted beneficial effects against JE in the mouse model.
It is the first evidence that intravenous MSCs could
serve as a potential adjunctive therapy for JE. Whether
this treatment modality can be applied to other types of
viral encephalitis warrants further investigation.
Additional files
Additional file 1: Figure S1. Characterization of mouse MSCs. (A) The
typical spindle-shape morphology of MSCs. (B,C) Analysis of the surface
makers on MSCs by flow cytometry. The positive markers CD44 and Sca-1
are >95% (B) and the negative markers I-A/I-E, CD34, and CD45 are <5%
(C). (D) Differentiation of MSCs into adipocytes, osteocytes and chondro-
cytes. (JPG 4926 kb)
Additional file 2: Table S1. Primer sequences used in this study.
(DOCX 15 kb)
Additional file 3: Table S2. Primary antibodies used in this study.
(DOCX 14 kb)
Additional file 4: Figure S2. At 10 and 22 dpi, mouse brains were
collected as described and the standard H&E staining protocol was
followed. (A) Severe meningitis in JEV-infected mice as indicated by arrows;
this disease state was significantly alleviated in the MSC treatment group at
10 dpi. (B) Perivascular cuffing with increased inflammatory cell infiltration
was more evident in JEV-infected mice compared with the MSC treatment
group at 10 dpi. (C) Phagocytosis of neurons by inflammatory cells was
apparent in JEV-infected mice at 10 dpi, while there was no significant
difference between the JEV and JEV +MSC groups regarding meningitis,
perivascular cuffing, and neuronal damage since the neuroinflammation
had been resolved at 22 dpi. (JPG 4626 kb)
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